HemOnc.org - A Hematology Oncology Wiki - Recent changes [en]

User:NolanaStrickland29

2012-05-20T12:35:39Z

New user account

User:SalaPhelan638

2012-05-20T11:33:39Z

New user account

User:OralieMauro814

2012-05-20T10:39:40Z

New user account

User:DarylStrait380

2012-05-19T20:06:28Z

New user account

User:IngallsFelipe855

2012-05-19T13:18:38Z

New user account

User:Jenniegreengin021

2012-05-19T10:51:24Z

New user account

User:Mfontes38

2012-05-19T05:14:23Z

New user account

Non-small cell lung cancer

2012-05-19T02:43:50Z

alphabatized regimens, links to example orders

Show changes

Example orders for Carboplatin (Paraplatin) and Pemetrexed (Alimta) in non-small cell lung cancer

2012-05-19T02:42:39Z

Created page with "'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.''' ==Carbop..."

New page

'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]].'''

==Carboplatin (Paraplatin) & Pemetrexed (Alimta)==
Original reference may be found at [[Non-small cell lung cancer#Carboplatin_.28Paraplatin.29_.26_Pemetrexed_.28Alimta.29|Carboplatin (Paraplatin) & Pemetrexed (Alimta)]]
===Example regimen #1===
*[[Carboplatin (Paraplatin)]] AUC 5 IV on day 1
**Infuse over 30-60 minutes.
*[[Pemetrexed (Alimta)]] 500 mg/m2 IV day 1
**Administer over 10 minutes. Administer after carboplatin.

'''21-day cycles x 6 cycles'''

Supportive medications:
*Ondansetron (Zofran) 8 mg IV 30 minutes prior to chemotherapy
*Lorazepam (Ativan) 0.5-1 mg PO/IV x 1 prn nausea/anxiety
*Prochlorperazine (Compazine) 10 mg PO x 1 prn nausea
*[[Dexamethasone (Decadron)]] 4 mg PO BID the day before, day of, and day after chemotherapy
*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM every 9 weeks, the first dose given at least 1 week prior to start of pemetrexed therapy
*Folic acid 1000 mcg PO daily, to start at least 1 week prior to start of pemetrexed therapy, to continue throughout therapy with pemetrexed

Hydration:
*500 ml NS and/or D5W at KVO rate as running IV for chemotherapy infusion. Give up to 500 ml NS and/or D5W as needed for IV compatibility.

Monitoring:
*On day 1 of each cycle: CBC with differential, absolute neutrophil count (ANC), BUN/Cr as part of a basic metabolic panel, alk phos, AST, ALT, total bilirubin, albumin, carcinoembryonic antigen
**Depending on provider preference and patient's tolerance, may simplify to CBC with differential, absolute neutrophil count (ANC), BUN/Cr
*On cycle 1 day 10, check nadir CBC with differential, absolute neutrophil count (ANC). Need for further nadir count checks to be determined by degree of cytopenias.
*Assess for response with CT scan after cycle 3

Outpatient medications:
*[[Dexamethasone (Decadron)]] as described above
*Lorazepam (Ativan) 0.5 mg PO Q6H prn anxiety, insomnia, nausea
*Ondansetron (Zofran) 4 mg PO Q6H prn nausea
*Prochlorperazine (Compazine) 10 mg PO x Q6H prn nausea
*Due to refractory nausea, in later cycles, we eventually added Aprepitant (Emend) 125 mg PO on day 1, 80 mg PO on days 2-3, and [[Dexamethasone (Decadron)]] use was extended to include day -1 through day 4

'''Clinical scenario & comments:'''
*60 year-old lady with stage IV adenocarcinoma of the lung, treated with first-line therapy for metastatic disease. Our institution's standard order set uses Carboplatin (Paraplatin) at AUC 5. This is reasonable in my view; the patient also had a history of pelvic radiation and chemotherapy for an unrelated malignancy many years ago. This was subsequently followed by [[Non-small cell lung cancer#Pemetrexed_.28Alimta.29|Pemetrexed (Alimta) maintenance therapy]].

User:GarverCaster839

2012-05-19T02:29:01Z

New user account

User:Khnguyen

2012-05-18T20:40:41Z

New user account

User:Hugaylord38

2012-05-18T18:20:48Z

New user account

User:Jenny1978

2012-05-18T04:14:54Z

New user account

User:PhilpottMellon355

2012-05-17T20:26:57Z

New user account

User:Life quote

2012-05-17T20:04:11Z

New user account

Drug index

2012-05-17T19:38:13Z

reference for chemotherapy dosing for obese adults

← Older revision		Revision as of 19:38, 17 May 2012
Line 2:		Line 2:
	*[[Antiemesis\|Antiemetic support]]		*[[Antiemesis\|Antiemetic support]]
	*[[Steroid conversions]]		*[[Steroid conversions]]
		+	*[http://jco.ascopubs.org/content/30/13/1553.long Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline]<ref>Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2012 May 1;30(13):1553-61. Epub 2012 Apr 2. [http://jco.ascopubs.org/content/30/13/1553.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/22473167 PubMed]</ref>
		+	*[http://www.theoncologypharmacist.com/sites/theoncologypharmacist.com/files/Chemotherapy%20Administration.pdf Chemotherapy Administration Sequence]<ref>Mancini R, Modlin J. Chemotherapy Administration Sequence: A Review of the Literature and Creation of a Sequencing Chart. J Hematol Oncol Pharm. 2011;1(1):17-25. [http://www.theoncologypharmacist.com/sites/theoncologypharmacist.com/files/Chemotherapy%20Administration.pdf link to original article]</ref> - with chemotherapy sequencing chart

	==A==		==A==
Line 282:		Line 284:

	==Reference==		==Reference==
-	~~# Mancini R, Modlin J. Chemotherapy Administration Sequence: A Review of the Literature and Creation of a Sequencing Chart. J Hematol Oncol Pharm. 2011;1(1):17-25. [http:~~/~~/www.theoncologypharmacist.com/sites/theoncologypharmacist.com/files/Chemotherapy%20Administration.pdf link to original article] - with chemotherapy sequencing chart~~	+	<references/>

Colon cancer

2012-05-17T03:45:36Z

CapeOx (XELOX): additional reference with follow-up results of trial

← Older revision		Revision as of 03:45, 17 May 2012
Line 19:		Line 19:
	XELOX: '''<u>XEL</u>'''oda, '''<u>OX</u>'''aliplatin		XELOX: '''<u>XEL</u>'''oda, '''<u>OX</u>'''aliplatin

-	===Regimen===	+	===Regimen #1, Schmoll, et al. 2007===
		+	''Note: This is the same trial as described by Haller, et al. 2011, but the schedule for [[Capecitabine (Xeloda)]] is slightly different.''
	*[[Capecitabine (Xeloda)]] 1000 mg/m2 PO BID, starting the evening of day 1, to continue through the morning of day 15 (28 total doses)		*[[Capecitabine (Xeloda)]] 1000 mg/m2 PO BID, starting the evening of day 1, to continue through the morning of day 15 (28 total doses)
		+	*[[Oxaliplatin (Eloxatin)]] 130 mg/m2 IV over 2 hours on day 1
		+
		+	'''21-day cycles x 8 cycles'''
		+
		+	===Regimen #2, Haller, et al. 2011===
		+	''Note: This is the same trial as described by Schmoll, et al. 2007, but the schedule for [[Capecitabine (Xeloda)]] is slightly different.''
		+	*[[Capecitabine (Xeloda)]] 1000 mg/m2 PO BID on days 1-14
	*[[Oxaliplatin (Eloxatin)]] 130 mg/m2 IV over 2 hours on day 1		*[[Oxaliplatin (Eloxatin)]] 130 mg/m2 IV over 2 hours on day 1

Line 27:		Line 35:
	===References===		===References===
	# Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill M, Sirzén F, Haller DG. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol. 2007 Jan 1;25(1):102-9. [http://jco.ascopubs.org/content/25/1/102.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/17194911 PubMed]		# Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill M, Sirzén F, Haller DG. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol. 2007 Jan 1;25(1):102-9. [http://jco.ascopubs.org/content/25/1/102.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/17194911 PubMed]
		+	# Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Gilberg F, Rittweger K, Schmoll HJ. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011 Apr 10;29(11):1465-71. Epub 2011 Mar 7. [http://jco.ascopubs.org/content/29/11/1465.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/21383294/ PubMed]

	==Fluorouracil (5-FU) & Folinic acid (Leucovorin)==		==Fluorouracil (5-FU) & Folinic acid (Leucovorin)==

User:Tolindler47

2012-05-17T00:24:01Z

New user account

User:Ddefenderfer94

2012-05-16T23:41:07Z

New user account

User:Family care

2012-05-16T22:18:22Z

New user account

User:ReikoSalvador61

2012-05-16T19:27:25Z

New user account

User:StarnesMerrifield685

2012-05-16T19:14:06Z

New user account

User:Heodis58

2012-05-16T15:59:47Z

New user account

User:LeblancStlaurent984

2012-05-16T07:15:33Z

New user account

User:Uk lifecover

2012-05-15T22:34:45Z

New user account

Colon cancer

2012-05-15T13:23:43Z

mFOLFOX 6: added mFOLFOX 6 +/- cetuximab reference

← Older revision		Revision as of 13:23, 15 May 2012
Line 88:		Line 88:
	*[[Oxaliplatin (Eloxatin)]] 85 mg/m2 IV over 2 hours on day 1		*[[Oxaliplatin (Eloxatin)]] 85 mg/m2 IV over 2 hours on day 1

-	'''14-day cycles x 12 cycles'''	+	'''14-day cycles x 12 cycles, to start within 10 weeks of surgery'''

	===References===		===References===
	# Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Colangelo LH, Lopa SH, Petrelli NJ, Goldberg RM, Atkins JN, Seay TE, Fehrenbacher L, O'Reilly S, Chu L, Azar CA, Wolmark N. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol. 2009 Jul 10;27(20):3385-90. Epub 2009 May 4. [http://jco.ascopubs.org/content/27/20/3385.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19414665 PubMed]		# Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Colangelo LH, Lopa SH, Petrelli NJ, Goldberg RM, Atkins JN, Seay TE, Fehrenbacher L, O'Reilly S, Chu L, Azar CA, Wolmark N. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol. 2009 Jul 10;27(20):3385-90. Epub 2009 May 4. [http://jco.ascopubs.org/content/27/20/3385.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/19414665 PubMed]
		+	# Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S, Kahlenberg MS, Shields AF, Quesenberry JT, Webb TA, Farr GH Jr, Pockaj BA, Grothey A, Goldberg RM. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012 Apr 4;307(13):1383-93. [http://jama.jamanetwork.com/article.aspx?articleid=1148329 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22474202 PubMed]

	==UFT & leucovorin==		==UFT & leucovorin==

User:Resingle21

2012-05-15T12:32:07Z

New user account

User:FraserHayashi93

2012-05-15T11:16:25Z

New user account

User:Aguirgis19

2012-05-15T10:23:00Z

New user account

User:DareenHiggs268

2012-05-15T09:42:47Z

New user account

User:RiciFogg376

2012-05-15T06:10:50Z

New user account

User:Hairloss info

2012-05-14T23:43:47Z

New user account

User:Hairline

2012-05-14T22:23:34Z

New user account

User:GastLemay632

2012-05-14T21:51:57Z

New user account

User:Tmohamed13

2012-05-14T12:22:38Z

New user account

User:Gnapoleon50

2012-05-14T05:34:29Z

New user account

User:LesherDunlop551

2012-05-14T05:22:27Z

New user account

User:Probe this

2012-05-13T23:59:21Z

New user account

Unknown primary

2012-05-13T23:17:20Z

also known as

New page

'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]].'''

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]].

Unknown primary tumor may also be referred to as carcinoma of unknown primary site, cancer of unknown primary (CUP), occult primary, or unknown primary carcinoma.

{{TOC limit|limit=3}}

=Adenocarcinoma or carcinoma NOS (not otherwise specified)=
==Bevacizumab (Avastin) & Erlotinib (Tarceva)==
===Regimen===
*[[Bevacizumab (Avastin)]] 10 mg/kg IV on days 1 & 15
**Infusion times for bevacizumab are 90 minutes for the first dose, then if tolerated, 60 minutes for the second dose, and 30 minutes for the third dose and later
*[[Erlotinib (Tarceva)]] 150 mg PO on days 1-28, 1 hour before or 2 hours after meals

'''28-day cycles'''

===References===
# Hainsworth JD, Spigel DR, Farley C, Thompson DS, Shipley DL, Greco FA; Minnie Pearl Cancer Research Network. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol. 2007 May 1;25(13):1747-52. [http://jco.ascopubs.org/content/25/13/1747.full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/17470864 PubMed]

==Carboplatin (Paraplatin) & Docetaxel (Taxotere)==
===Regimen #1, Pentheroudakis, et al. 2008===
*[[Carboplatin (Paraplatin)]] AUC 5 IV over 30 minutes on day 1, given second
*[[Docetaxel (Taxotere)]] 75 mg/m2 IV over 30 minutes on day 1, given first

'''21-day cycles x up to 8 cycles'''

Supportive medications:
*[[Dexamethasone (Decadron)]] 8 mg PO BID the day before chemotherapy
*[[Dexamethasone (Decadron)]] 16 mg IV prior to chemotherapy, on the day of chemotherapy
*Ondansetron (Zofran) 8 mg IV prior to chemotherapy
*Ranitidine (Zantac) 100 mg IV prior to chemotherapy
*Dimethindene maleate 0.1 mg/kg IV prior to chemotherapy

===Regimen #2, Greco, et al. 2000===
*[[Carboplatin (Paraplatin)]] AUC 6 IV over 20 minutes on day 1, given second
*[[Docetaxel (Taxotere)]] 65 mg/m2 IV over 1 hour on day 1, given first

'''21-day cycles x 4-8 cycles'''

Supportive medications:
*[[Dexamethasone (Decadron)]] 8 mg PO BID the day before, the day of, and day after chemotherapy
*Ondansetron (Zofran) 32 mg IV or Granisetron (Kytril) 10 mcg/kg IV 15 minutes prior to chemotherapy

===References===
# Greco FA, Erland JB, Morrissey LH, Burris HA 3rd, Hermann RC, Steis R, Thompson D, Gray J, Hainsworth JD. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol. 2000 Feb;11(2):211-5. [http://annonc.oxfordjournals.org/content/11/2/211.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/10761758 PubMed]
# Pentheroudakis G, Briasoulis E, Kalofonos HP, Fountzilas G, Economopoulos T, Samelis G, Koutras A, Karina M, Xiros N, Samantas E, Bamias A, Pavlidis N; Hellenic Cooperative Oncology Group. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study. Acta Oncol. 2008;47(6):1148-55. [http://informahealthcare.com/doi/full/10.1080/02841860701843043 link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/18607872 PubMed]

==Carboplatin (Paraplatin) & Paclitaxel (Taxol)==
===Regimen===
*[[Carboplatin (Paraplatin)]] AUC 6 IV over 30 minutes on day 1, given first
*[[Paclitaxel (Taxol)]] 200 mg/m2 IV over 3 hours on day 1, given second

'''21-day cycles x 6-8 cycles'''

Supportive medications:
*[[Methylprednisolone (Solu-Medrol)]] 32 mg PO 24 and 12 hours before paclitaxel, and 10 minutes before carboplatin
*[[Dexamethasone (Decadron)]] 16 mg IV over 10 minutes prior to chemotherapy
*Diphenhydramine (Benadryl) 50 mg IV or dimethindene maleate 0.1 mg/kg IV over 10 minutes prior to chemotherapy
*Ranitidine (Zantac) 100 mg IV over 10 minutes prior to chemotherapy
*Ondansetron (Zofran) 8 mg IV after the above premedications
*[[Filgrastim (Neupogen)]] 300 mcg SC suggested on days 5-12

===References===
# Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, Xiros N, Skarlos D, Christodoulou C, Kosmidis P, Pavlidis N. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol. 2000 Sep;18(17):3101-7. [http://jco.ascopubs.org/content/18/17/3101.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/10963638 PubMed]

==Carboplatin (Paraplatin), Paclitaxel (Taxol), Etoposide (Vepesid)==
===Regimen===
*[[Carboplatin (Paraplatin)]] AUC 6 IV over 20-30 minutes on day 1
*[[Paclitaxel (Taxol)]] 200 mg/m2 IV over 1 hour on day 1
*[[Etoposide (Vepesid)]] 50 mg PO on days 1, 3, 5, 7, 9, and 100 mg PO on days 2, 4, 6, 8, 10

'''21-day cycles x 4-8 cycles'''

Supportive medications:
*[[Dexamethasone (Decadron)]] 20 mg PO 12 hours and 4 hours prior to paclitaxel
*[[Dexamethasone (Decadron)]] 20 mg IV 30 minutes prior to paclitaxel
*Diphenhydramine (Benadryl) 50 mg IV 30 minutes prior to paclitaxel
*Cimetidine (Tagamet) 300 mg IV 30 minutes prior to paclitaxel

===References===
# Greco FA, Burris HA 3rd, Erland JB, Gray JR, Kalman LA, Schreeder MT, Hainsworth JD. Carcinoma of unknown primary site. Cancer. 2000 Dec 15;89(12):2655-60. [http://onlinelibrary.wiley.com/doi/10.1002/1097-0142%2820001215%2989:12%3C2655::AID-CNCR19%3E3.0.CO;2-9/full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/11135228 PubMed]
# Hainsworth JD, Spigel DR, Clark BL, Shipley D, Thompson DS, Farley C, West-Osterfield K, Lane CM, Cescon T, Bury MJ, Greco FA. Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. Cancer J. 2010 Jan-Feb;16(1):70-5. [http://journals.lww.com/journalppo/pages/articleviewer.aspx?year=2010&issue=02000&article=00013&type=abstract link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/20164695 PubMed]

==Carboplatin (Paraplatin), Paclitaxel (Taxol), Gemcitabine (Gemzar)==
===Regimen===
*[[Carboplatin (Paraplatin)]] AUC 5 IV over 20-30 minutes on day 1
*[[Paclitaxel (Taxol)]] 200 mg/m2 IV over 1 hour on day 1
*[[Gemcitabine (Gemzar)]] 1000 mg/m2 IV on days 1 & 8

'''21-day cycles'''

Supportive medications:
*Corticosteroids IV 30 minutes prior to paclitaxel
*Diphenhydramine (Benadryl) 50 mg IV 30 minutes prior to paclitaxel
*Cimetidine (Tagamet) 300 mg IV 30 minutes prior to paclitaxel

===References===
# Greco FA, Burris HA 3rd, Litchy S, Barton JH, Bradof JE, Richards P, Scullin DC Jr, Erland JB, Morrissey LH, Hainsworth JD. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol. 2002 Mar 15;20(6):1651-6. [http://jco.ascopubs.org/content/20/6/1651.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/11896116 PubMed]

==Cisplatin (Platinol) & Docetaxel (Taxotere)==
===Regimen===
*[[Cisplatin (Platinol)]] 75 mg/m2 IV over 1 hour on day 1
*[[Docetaxel (Taxotere)]] 75 mg/m2 IV over 1 hour on day 1

'''21-day cycles x up to 8 cycles'''

Supportive medications:
*[[Dexamethasone (Decadron)]] 8 mg PO BID the day before, the day of, and day after chemotherapy
*Suggested: [[Dexamethasone (Decadron)]] 20 mg IV 15 minutes prior to cisplatin
*2 liters of normal saline with chemotherapy
*Ondansetron (Zofran) 32 mg IV or Granisetron (Kytril) 10 mcg/kg IV 15 minutes prior to cisplatin
*Ondansetron (Zofran) 8 mg PO TID on days 2-6

===References===
# Greco FA, Erland JB, Morrissey LH, Burris HA 3rd, Hermann RC, Steis R, Thompson D, Gray J, Hainsworth JD. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol. 2000 Feb;11(2):211-5. [http://annonc.oxfordjournals.org/content/11/2/211.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/10761758 PubMed]

==Cisplatin (Platinol), Etoposide (Vepesid), Bleomycin (Blenoxane)==
===Regimen===
*[[Cisplatin (Platinol)]] 20 mg/m2 IV on days 1-5
*[[Etoposide (Vepesid)]] 100 mg/m2 IV on days 1-5
*[[Bleomycin (Blenoxane)]] 30 units IV on days 1, 8, 15

'''21-day cycles'''

===References===
# Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol. 1992 Jun;10(6):912-22. [http://jco.ascopubs.org/content/10/6/912.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/1375284 PubMed]

==Cisplatin (Platinol) & Gemcitabine (Gemzar)==
===Regimen===
*[[Cisplatin (Platinol)]] 100 mg/m2 IV on day 1
*[[Gemcitabine (Gemzar)]] 1250 mg/m2 IV on days 1 & 8

'''21-day cycles'''

===References===
# Culine S, Lortholary A, Voigt JJ, Bugat R, Théodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y, Allouache J, Goupil A, Négrier S, Viala J, Petrow P, Bouzy J, Laplanche A, Fizazi K; Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol. 2003 Sep 15;21(18):3479-82. [http://jco.ascopubs.org/content/21/18/3479.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/12972523 PubMed] content property of HemOnc.org
# Gross-Goupil M, Fourcade A, Blot E, Penel N, Négrier S, Culine S, Chaigneau L, Lesimple T, Priou F, Lortholary A, Kaminsky MC, Provencal J, Voog E, Bouzy J, Laplanche A, Fizazi K. Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial. Eur J Cancer. 2012 Mar;48(5):721-7. Epub 2012 Feb 6. [http://www.ejcancer.info/article/S0959-8049%2812%2900018-4/abstract link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/22317952 PubMed]

==Cisplatin (Platinol) & Irinotecan (Camptosar)==
===Regimen===
*[[Cisplatin (Platinol)]] 80 mg/m2 IV on day 1
*[[Irinotecan (Camptosar)]] 150 mg/m2 IV on day 1

'''21-day cycles'''

===References===
# Culine S, Lortholary A, Voigt JJ, Bugat R, Théodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y, Allouache J, Goupil A, Négrier S, Viala J, Petrow P, Bouzy J, Laplanche A, Fizazi K; Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol. 2003 Sep 15;21(18):3479-82. [http://jco.ascopubs.org/content/21/18/3479.long link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/12972523 PubMed]

==Gemcitabine (Gemzar) & Docetaxel (Taxotere)==
===Regimen===
*[[Gemcitabine (Gemzar)]] 1000 mg/m2 IV over 30 minutes on days 1 & 8
*[[Docetaxel (Taxotere)]] 75 mg/m2 IV over 1 hour on day 8

'''21-day cycles x up to 6 cycles'''

Supportive medications:
*Corticosteroids PO the day before, the day of, and day after docetaxel

===References===
# Pouessel D, Culine S, Becht C, Ychou M, Romieu G, Fabbro M, Cupissol D, Pinguet F. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer. 2004 Mar 15;100(6):1257-61. [http://onlinelibrary.wiley.com/doi/10.1002/cncr.20100/full link to original article] '''contains verified protocol''' [http://www.ncbi.nlm.nih.gov/pubmed/15022294 PubMed]

=Squamous cell carcinoma=
==Cisplatin (Platinol), Docetaxel (Taxotere), Fluorouracil (5-FU)==
===Regimen===
''The NCCN, Occult Primary version 1.2012 lists this as a suitable regimen in this setting. The Pointreau, et al. 2009 regimen was for larynx and hypopharynx cancer, and the regimen also involved chemoradiation +/- surgery.''
*[[Cisplatin (Platinol)]] 75 mg/m2 IV on day 1
*[[Docetaxel (Taxotere)]] 75 mg/m2 IV on day 1
*[[Fluorouracil (5-FU)]] 750 mg/m2/day IV continuous infusion over 120 hours on days 1-5

'''21-day cycles x 3 cycles'''

Supportive medications:
*1 liter normal saline before and after cisplatin +/- mannitol, potassium chloride, magnesium sulfate
*[[Dexamethasone (Decadron)]] 8 mg PO daily the day before, the day of, and day after chemotherapy
*Ciprofloxacin (Cipro) 1000 mg PO (reference did not specify, but assume 500 mg BID) on days 5-15

===References===
# Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, Faivre S, Guerrif S, Alfonsi M, Calais G. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009 Apr 1;101(7):498-506. Epub 2009 Mar 24. [http://jnci.oxfordjournals.org/content/101/7/498.long link to original article] '''contains verified protocol'''--see comment above [http://www.ncbi.nlm.nih.gov/pubmed/19318632 PubMed]

==Cisplatin (Platinol), Paclitaxel (Taxol), Fluorouracil (5-FU)==
===Regimen===
''The NCCN, Occult Primary version 1.2012 lists this as a suitable regimen in this setting. The Hitt, et al. 2005 regimen was for head and neck cancer, and the regimen also involved chemoradiation.''
*[[Cisplatin (Platinol)]] 100 mg/m2 IV on day 2
*[[Paclitaxel (Taxol)]] 175 mg/m2 IV over 3 hours on day 1
*[[Fluorouracil (5-FU)]] 500 mg/m2/day IV continuous infusion over 120 hours on days 2-6

'''21-day cycles x 3 cycles'''

Supportive medications:
*[[Dexamethasone (Decadron)]], Diphenhydramine (Benadryl), and Cimetidine (Tagamet) or Ranitidine (Zantac) 30 minutes before paclitaxel

===References===
# Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A, Isla D, Vega ME, Martí JL, Lobo F, Pastor P, Valentí V, Belón J, Sánchez MA, Chaib C, Pallarés C, Antón A, Cervantes A, Paz-Ares L, Cortés-Funes H. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005 Dec 1;23(34):8636-45. Epub 2005 Nov 7. [http://jco.ascopubs.org/content/23/34/8636.long link to original article] '''contains verified protocol'''--see comment above [http://www.ncbi.nlm.nih.gov/pubmed/16275937 PubMed]

=Neuroendocrine tumors=
*Poorly differentiated or small cell tumors can be treated with [[small cell lung cancer]] regimens.
*Moderate to well-differentiated neuroendocrine tumors can be treated with regimens for [[neuroendocrine tumors]].

User:MedleyAmundson366

2012-05-13T21:22:02Z

New user account

Mesothelioma

2012-05-13T19:58:07Z

Created page with "'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.''' Is there..."

New page

User:Flyagawiki121as

2012-05-13T14:15:04Z

New user account

User:Baabraham69

2012-05-13T13:55:21Z

New user account

User:SadaPersinger358

2012-05-13T02:55:03Z

New user account